Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide.

Cibeira MT, de Larrea CF, Navarro A, Díaz T, Fuster D, Tovar N, Rosiñol L, Monzó M, Bladé J.

Leuk Res. 2011 Sep;35(9):1178-83. doi: 10.1016/j.leukres.2011.02.009. Epub 2011 Mar 23.

PMID:
21435719
3.

Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.

Cibeira MT, Rosiñol L, Ramiro L, Esteve J, Torrebadell M, Bladé J.

Eur J Haematol. 2006 Dec;77(6):486-92. Epub 2006 Sep 15.

PMID:
16978238
4.

Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.

Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N, Vangsted AJ.

Int J Cancer. 2012 Sep 1;131(5):E636-42. doi: 10.1002/ijc.27387. Epub 2012 Jan 31.

5.

Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.

Mileshkin L, Honemann D, Gambell P, Trivett M, Hayakawa Y, Smyth M, Beshay V, Ritchie D, Simmons P, Milner AD, Zeldis JB, Prince HM.

Haematologica. 2007 Aug;92(8):1075-82. Epub 2007 Jul 20.

6.

Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.

Chang H, Jiang A, Qi C, Trieu Y, Chen C, Reece D.

Leuk Lymphoma. 2010 Nov;51(11):2084-91. doi: 10.3109/10428194.2010.524325. Epub 2010 Oct 7.

PMID:
20929319
7.

Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects.

Corso A, Zappasodi P, Barbarano L, Petrucci MT, Palumbo A, Caravita T, Mangiacavalli S, Cafro AM, Varettoni M, Gay F, Morra E, Lazzarino M.

Leuk Res. 2009 Sep;33(9):e145-9. doi: 10.1016/j.leukres.2009.03.015. Epub 2009 Apr 16.

PMID:
19375164
8.

Thalidomide in refractory and relapsing multiple myeloma.

Bladé J, Esteve J, Rosiñol L, Perales M, Montoto S, Tuset M, Montserrat E.

Semin Oncol. 2001 Dec;28(6):588-92.

PMID:
11740814
9.

Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug.

Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicz M, Ben-Bassat I.

Br J Haematol. 2000 Feb;108(2):391-3.

PMID:
10691870
10.

Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.

Vangsted AJ, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Gregersen H, Nexø BA, Vogel U.

Ann Hematol. 2011 Oct;90(10):1173-81. doi: 10.1007/s00277-011-1194-3. Epub 2011 Feb 24.

PMID:
21347685
11.

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.

Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM.

Blood. 2008 Dec 1;112(12):4445-51. doi: 10.1182/blood-2008-02-141614. Epub 2008 Sep 17.

12.

Thalidomide and dexamethasone combination for refractory multiple myeloma.

Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, Vervessou E, Samantas E, Papadimitriou C, Economou O, Gika D, Panayiotidis P, Christakis I, Anagnostopoulos N.

Ann Oncol. 2001 Jul;12(7):991-5.

13.

Thalidomide treatment of resistant or relapsed multiple myeloma patients.

Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepnuch H, Hellmann A, Wolska-Smolen T, Skotnicki A, Manko J; Polish Multiple Myeloma Study Group.

Haematologica. 2001 Apr;86(4):404-8.

14.

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

Mileshkin L, Biagi JJ, Mitchell P, Underhill C, Grigg A, Bell R, McKendrick J, Briggs P, Seymour JF, Lillie K, Smith JG, Zeldis JB, Prince HM.

Blood. 2003 Jul 1;102(1):69-77. Epub 2003 Mar 13.

15.

A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.

Prince HM, Mileshkin L, Roberts A, Ganju V, Underhill C, Catalano J, Bell R, Seymour JF, Westerman D, Simmons PJ, Lillie K, Milner AD, Iulio JD, Zeldis JB, Ramsay R.

Clin Cancer Res. 2005 Aug 1;11(15):5504-14.

16.

Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States.

Dimopoulos MA, Anagnostopoulos A.

Semin Hematol. 2003 Oct;40(4 Suppl 4):8-16. Review.

PMID:
15015891
17.

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Anderson KC.

Blood. 2009 Jul 23;114(4):772-8. doi: 10.1182/blood-2008-12-196238. Epub 2009 May 26.

18.

Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan.

Dumontet C, Landi S, Reiman T, Perry T, Plesa A, Bellini I, Barale R, Pilarski LM, Troncy J, Tavtigian S, Gemignani F.

Bone Marrow Transplant. 2010 Aug;45(8):1316-24. doi: 10.1038/bmt.2009.335. Epub 2009 Dec 7.

PMID:
19966851
19.

Antitumor activity of thalidomide in refractory multiple myeloma.

Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B.

N Engl J Med. 1999 Nov 18;341(21):1565-71. Erratum in: N Engl J Med 2000 Feb 3;342(5):364.

20.

Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma.

Neben K, Mytilineos J, Moehler TM, Preiss A, Kraemer A, Ho AD, Opelz G, Goldschmidt H.

Blood. 2002 Sep 15;100(6):2263-5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk